In vivo cellular imaging of lymphocyte trafficking by MRI: A tumor model approach to cell-based anticancer therapy

Magnetic Resonance in Medicine

Volumn 56, Issue 3, 2006, Pages 498-508

  Smirnov, Pierre ^a,c   Lavergne, Elise ^b   Gazeau, Florence ^c   Lewin, Maïté ^a   Boissonnas, Alexandre ^b   Doan, Bich Thuy ^d   Gillet, Brigitte ^d   Combadière, Christophe ^b   Combadière, Béhazine ^b   Clément, Olivier ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DIDEROT   (France)

^d CNRS   (France)

Author keywords

Cell therapy; In vivo cellular imaging; Lymphocyte trafficking; MRI; Superparamagnetic iron oxide nanoparticles

Indexed keywords

HEMATITE; LYMPHOCYTES; MAGNETIC NANOPARTICLES; MAGNETIC RESONANCE IMAGING; MAMMALS; TUMORS;

ANTI-CANCER THERAPIES; CELL THERAPY; CELLULAR IMAGING; HIGH RESOLUTION; HIGH-RESOLUTION IMAGING; MAGNETIC IRON OXIDES; MAGNETIC SORTING; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES;

CYTOLOGY;

NANOPARTICLE; OVALBUMIN; SUPERPARAMAGNETIC IRON OXIDE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LABELING; CELL SELECTION; CELLULAR DISTRIBUTION; CELLULAR IMAGING; CONTROLLED STUDY; DIAGNOSTIC IMAGING; EX VIVO STUDY; FEMALE; IMAGE ENHANCEMENT; IMMUNOCOMPETENT CELL; IN VIVO STUDY; LYMPHOCYTE HOMING; LYMPHOCYTE MIGRATION; MAGNETIC SEPARATION; MOLECULAR IMAGING; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PROTEIN EXPRESSION; SPLEEN CELL; SUBCUTANEOUS TISSUE TUMOR; TREATMENT OUTCOME; TUMOR MODEL;

EID: 33748370299     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.20996     Document Type: Article

References (39)

1. Dove A. Cell-based therapies go live. Nat Biotechnol 2002;20:339-343.
2. Jalili A, Stoklosa T, Giermasz A, Olszewska D, Wilczynski G, Jakobisiak M, Golab J. A single injection of immature dendritic cells is able to induce antitumour response against a murine colon adenocarcinoma with a low apoptotic index. Oncol Rep 2002;9:991-994.
3. Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, Tesar P, Strong R, Leggett B, Powell L, Maddern G, Ellem K, Cooksley G. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002;17:889-896.
4. Cardoso AA, Veiga JP, Ghia P, Afonso HM, Haining WN, Sallan SE, Nadler LM. Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies. Blood 1999;94:3531-3540.
5. Muller L, Provenzani C, Faul C, Pawelec G. Recognition of chronic myelogenous leukaemia cells by autologous T lymphocytes primed in vitro against the patient's dendritic cells. Br J Haematol 2001;112:740-748.
6. Fujii S, Fujimoto K, Shimizu K, Ezaki T, Kawano F, Takatsuki K, Kawakita M, Matsuno K. Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients. Cancer Res 1999;59:2150-2158.
7. Flamand V, Lespagnard L, Thielemans K, Leo O, Urbain J, Moser M. Enhancement of a spontaneous immune response against a B-cell lymphoma by dendritic cells leads to protection against the tumor. Ann NY Acad Sci 1993;690:382-384.
8. Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP, Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res 2001;61:6219-6226.
9. Titzer S, Christensen O, Manzke O, Tesch H, Wolf J, Emmerich B, Carsten C, Diehl V, Bohlen H. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000;108:805-816.
10. Hardy J, Edinger M, Bachmann MH, Negrin RS, Fathman CG, Contag CH. Bioluminescence imaging of lymphocyte trafficking in vivo. Exp Hematol 2001;29:1353-1360.
11. Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002;2:266-276.
12. Osman S, Danpure HJ. The use of 2-[18F]fluoro-2-deoxy-D-glucose as a potential in vitro agent for labelling human granulocytes for clinical studies by positron emission tomography. Int J Rad Appl Instrum B 1992;19:183-190.
13. Roddie ME, Peters AM, Danpure HJ, Osman S, Henderson BL, Lavender JP, Carroll MJ, Neirinckx RD, Kelly JD. Inflammation: imaging with Tc-99m HMPAO-labeled leukocytes. Radiology 1988;166:767-772.
14. Bulte JW, Laughlin PG, Jordan EK, Tran VA, Vymazal J, Frank JA. Tagging of T cells with superparamagnetic iron oxide: uptake kinetics and relaxometry. Acad Radiol 1996;3(Suppl 2):S301-S303.
15. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, Basilion JP. In vivo magnetic resonance imaging of transgene expression. Nat Med 2000;6:351-355.
16. Dodd SJ, Williams M, Suhan JP, Williams DS, Koretsky AP, Ho C. Detection of single mammalian cells by high-resolution magnetic resonance imaging. Biophys J 1999;76(Pt 1):103-109.
17. Yeh TC, Zhang W, Ildstad ST, Ho C. In vivo dynamic MRI tracking of rat T-cells labeled with superparamagnetic iron-oxide particles. Magn Reson Med 1995;33:200-208.
18. Jung CW. Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995;13:675-691.
19. Schulze E, Ferracci Jr JT, Poss K, Lapointe L, Bogdanova A, Weissleder R. Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro. Invest Radiol 1995;30:604-610.
20. Moore A, Weissleder R, Bogdanov Jr A. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging 1997;7:1140-1145.
21. Wunderbaldinger P, Josephson L, Weissleder R. Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconjug Chem 2002;13:264-268.
22. Josephson L, Tung CH, Moore A, Weissleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem 1999;10:186-191.
23. Kircher MF, Allport JR, Graves EE, Love V, Josephson L, Lichtman AH, Weissleder R. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res 2003;63:6838-6846.
24. Dodd CH, Hsu HC, Chu WJ, Yang P, Zhang HG, Mountz Jr JD, Zinn K, Forder J, Josephson L, Weissleder R, Mountz JM, Mountz JD. Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. J Immunol Methods 2001;256:89-105.
25. Lewin M, Carlesso N, Tung CH, Tang XW, Gory D, Scadden DT, Weissleder R. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000;18:410-414.
26. Bulte JW, Zhang S, van Gelderen P, Herynek V, Jordan EK, Duncan ID, Frank JA. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. Proc Natl Acad Sci USA 1999;96:15256-15261.
27. Bulte JW, Douglas T, Witwer B, Zhang SC, Strable E, Lewis BK, Zywicke H, Miller B, van Gelderen P, Moskowitz BM, Duncan ID, Frank JA. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol 2001;19:1141-1147.
28. Metz S, Bonaterra G, Rudelius M, Settles M, Rummeny EJ, Daldrup-Link HE. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. Eur Radiol 2004;14:1851-1858.
29. Matuszewski L, Persigehl T, Wall A, Schwindt W, Tombach B, Fobker M, Poremba C, Ebert W, Heindel W, Bremer C. Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. Radiology 2005;235:155-161.
30. Wilhelm C, Billotey C, Roger J, Pons JN, Bacri JC, Gazeau F. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials 2003;24:1001-1011.
31. Wilhelm C, Gazeau F, Roger J, Pons JN, Bacri JC. Interaction of anionic superparamagnetic nanoparticles with cells: kinetic analyses of membrane adsorption and subsequent internalization. Langmuir 2002;18:8148-8155.
32. Smirnov P, Gazeau F, Lewin M, Bacri JC, Siauve N, Vayssettes C, Cuenod CA, Clement O. In vivo cellular imaging of magnetically labeled hybridomas in the spleen with a 1.5-T clinical MRI system. Magn Reson Med 2004;52:73-79.
33. Wilhelm C, Gazeau F, Bacri JC. Magnetophoresis and ferromagnetic resonance of magnetically labeled cells. Eur Biophys J 2002;31:118-125.
34. Riviere C, Boudghene FP, Gazeau F, Roger J, Pons JN, Laissy JP, Allaire E, Michel JB, Letourneur D, Deux JF. Iron oxide nanoparticle-labeled rat smooth muscle cells: cardiac MR imaging for cell graft monitoring and quantitation. Radiology 2005;235:959-967.
35. Boissonnas A, Combadiere C, Lavergne E, Maho M, Blanc C, Debre P, Combadiere B. Antigen distribution drives programmed antitumor CD8 cell migration and determines its efficiency. J Immunol 2004;173:222-229.
36. Billotey C, Wilhelm C, Devaud M, Bacri JC, Bittoun J, Gazeau F. Cell internalization of anionic maghemite nanoparticles: Quantitative effect on magnetic resonance imaging. Magn Reson Med 2003;49:646-654.
37. Daldrup-Link HE, Meier R, Rudelius M, Piontek G, Piert M, Metz S, Settles M, Uherek C, Wels W, Schlegel J, Rummeny EJ. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol 2005;15:4-13.
38. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, Oyen WJ, Bonenkamp JJ, Boezeman JB, Adema GJ, Bulte JW, Scheenen TW, Punt CJ, Heerschap A, Figdor CG. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005;23:1407-1413.
39. Chambon C, Clement O, Le Blanche A, Schouman-Claeys E, Frija G. Superpaiamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. Magn Reson Imaging 1993;11:509-519.